Kim Eun Young, Hyun Kee Hoon, Park Yong Lai, Park Chan Heun, Yun Ji-Sup
Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg Treat Res. 2017 Jan;92(1):1-8. doi: 10.4174/astr.2017.92.1.1. Epub 2016 Dec 30.
The measurement of serum thyroglobulin (Tg) of papillary thyroid carcinoma patients, 12 months after total thyroidectomy and radioactive iodine (RAI) ablation following thyroxine hormone withdrawal (T4-off Tg) or recombinant human thyroid-stimulating hormone stimulation (rhTSH-Tg), is standard method for monitoring disease status. The aim of this study was to find predictive factors for detectable T4-off Tg during follow-up.
A retrospective review was conducted of 329 patients who underwent total thyroidectomy and RAI ablation between October 2008 and August 2012. Subjects were assigned to high (>1 ng/mL, n = 53) and low (≤1 ng/mL, n = 276) groups, based on T4-off Tg measured 12 months postoperatively. Demographic and clinicopathological characteristics at diagnosis and follow-up were compared between the 2 groups.
The low and high T4-off Tg groups differed with respect to tumor size, preoperative Tg, ablative Tg, cervical lymph node metastasis, thyroglobulinemia out of proportion to results of diagnostic whole body scan, and American Thyroid Association 3-level stratification and restratification. Multivariate analysis confirmed that ablative Tg > 1.0 ng/mL (odds ratio [OR], 10.801; P = 0.001), more than 5 cervical lymph node metastasis (OR, 6.491; P = 0.003), and thyroglobulinemia out of proportion (OR, 9.221; P = 0.000) were risk factors.
Ablative Tg >1.0 ng/mL, more than 5 cervical lymph node metastasis, and thyroglobulinemia out of proportion were independent factors for T4-off Tg >1 ng/mL 12 months postoperative. In low-risk patients without these risk factors, the possible omission of Tg measurements could be considered during follow-up.
对于甲状腺乳头状癌患者,在全甲状腺切除及甲状腺激素撤停(T4 停药)后放射性碘(RAI)消融 12 个月时测定血清甲状腺球蛋白(Tg),或在重组人促甲状腺激素刺激(rhTSH)下测定血清甲状腺球蛋白(Tg),是监测疾病状态的标准方法。本研究的目的是寻找随访期间可检测到 T4 停药后 Tg 的预测因素。
对 2008 年 10 月至 2012 年 8 月期间接受全甲状腺切除及 RAI 消融的 329 例患者进行回顾性研究。根据术后 12 个月测定的 T4 停药后 Tg,将受试者分为高(>1 ng/mL,n = 53)、低(≤1 ng/mL,n = 276)两组。比较两组诊断时及随访时的人口统计学和临床病理特征。
低 T4 停药后 Tg 组和高 T4 停药后 Tg 组在肿瘤大小、术前 Tg、消融后 Tg、颈部淋巴结转移、甲状腺球蛋白血症与诊断性全身扫描结果不成比例以及美国甲状腺协会 3 级分层和重新分层方面存在差异。多因素分析证实,消融后 Tg>1.0 ng/mL(比值比[OR],10.801;P = 0.001)、颈部淋巴结转移超过 5 个(OR,6.491;P = 0.003)以及甲状腺球蛋白血症不成比例(OR,9.221;P = 0.000)是危险因素。
消融后 Tg>1.0 ng/mL、颈部淋巴结转移超过 5 个以及甲状腺球蛋白血症不成比例是术后 12 个月 T4 停药后 Tg>1 ng/mL 的独立因素。对于无这些危险因素的低风险患者,随访期间可考虑可能省略 Tg 测量。